60 DEGREES PHARMACEUTICALS INC
For the period ended Mar 31, 2024. Filed May 15, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 15, 2024
SXTP$0.52-4.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Condensed Statements of Shareholders’ Deficit
CONSOLIDATED CONDENSED STATEMENTS OF SHAREHOLDERS’ EQUITY (DEFICIT) (UNAUDITED)
| Series A Preferred Stock · Common Stock · Additional Paid-In · Accumulated · Accumulated Other Comprehensive · Total Shareholders’ Equity (Deficit) Attributable · Noncontrolling Interest on · Total Shareholders’ Equity | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares · Amount · Capital · Deficit · Income (Loss) · to 60P · Shareholders · (Deficit) | |||||||||||
| Balance—December 31, 2022 | - | $ | - | 2,386,009 | $239 | $5,164,461 | $(28,815,148) | $73,708 | $(23,576,740) | $(572,320) | $(24,149,060) |
| Cancellation of common stock | - | - | (1,451,000) | (145) | 145 | - | - | - | - | - | |
| Share-based compensation to vendors for services | - | - | 1,443,000 | 144 | 5,378,764 | - | - | 5,378,908 | - | 5,378,908 | |
| Net foreign translation loss | - | - | - | - | - | - | (1,290) | (1,290) | - | (1,290) | |
| Net (loss) income | - | - | - | - | - | (2,600,061) | - | (2,600,061) | 2,527 | (2,597,534) | |
| Balance— March 31, 2023 | - | $ | - | 2,378,009 | $238 | $10,543,370 | $(31,415,209) | $72,418 | $(20,799,183) | $(569,793) | $(21,368,976) |
| Series A Preferred Stock · Common Stock · Additional Paid-In · Accumulated · Accumulated Other Comprehensive · Total Shareholders ’Equity (Deficit) Attributable · Noncontrolling Interest on · Total Shareholders’ Equity | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Capital | Deficit | Income (Loss) | to 60P | Shareholders | (Deficit) | |
| Balance—December 31, 2023 | 78,803 | $9,858,040 | 5,810,089 | $581 | $27,456,802 | $(32,580,850) | $135,561 | $4,870,134 | $(72,038) | $4,798,096 |
| Issuance of common stock and warrants, net of underwriting discounts and offering costs paid at closing and deferred offering costs | - | - | 5,260,951 | 526 | 1,897,770 | - | - | 1,898,296 | - | 1,898,296 |
| Issuance of common stock upon exercise of Pre-Funded Warrants | - | - | 499,538 | 50 | 4,945 | - | - | 4,995 | - | 4,995 |
| Issuance of shares for RSUs | - | - | 192,000 | 19 | (19) | - | - | - | - | - |
| Net foreign translation loss | - | - | - | - | - | - | (3,894) | (3,894) | - | (3,894) |
| Net income (loss) | - | - | - | - | - | 430,470 | - | 430,470 | (2,485) | 427,985 |
| Balance— March 31, 2024 | 78,803 | $9,858,040 | 11,762,578 | $1,176 | $29,359,498 | $(32,150,380) | $131,667 | $7,200,001 | $(74,523) | $7,125,478 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.